Skip to Main Content

A Study of Psilocybin for Major Depressive Disorder (MDD)

Conditions

Mental Health & Behavioral Research

Phase II

What is the purpose of this trial?

Eighty participants, ages 21 to 65, who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for major depressive disorder (MDD) will be stratified by study site and randomized with a 1-to-1 allocation under double-blind conditions to receive a single 25 mg oral dose of psilocybin or a single 100 mg oral dose of niacin. Niacin will serve as an active placebo.

The purpose of this study is to evaluate the potential efficacy of a single 25 mg oral dose of psilocybin for MDD compared to the active placebo in otherwise medically-healthy participants, assessed as the difference between groups in changes in depressive symptoms from Baseline to Day 8 post-dose.

  • Trial with
    Usona Institute
  • Start Date
    11/03/2019
  • End Date
    02/27/2021
Trial Image

For more information about this study, contact:

Jane Wanyiri

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    03/18/2020
  • Study HIC
    #2000025986